These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 22504918

  • 21. Treatment failure with new hepatitis C drugs.
    Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P.
    Expert Opin Pharmacother; 2012 Feb; 13(3):313-23. PubMed ID: 22242928
    [Abstract] [Full Text] [Related]

  • 22. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P, Sarrazin C.
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Treatment of hepatitis C: current status and perspectives].
    Pol S, Corouge M.
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
    Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, Gupta S, Hughes E, Chase R, Lahser F, Barnard RJ, Howe AY, Howe JA.
    J Hepatol; 2013 Jul; 59(1):31-7. PubMed ID: 23454058
    [Abstract] [Full Text] [Related]

  • 34. Hepatitis C virus resistance to protease inhibitors.
    Halfon P, Locarnini S.
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [Abstract] [Full Text] [Related]

  • 35. [New treatments for hepatitis C, which targets, what timeline?].
    Goossens N, Negro F.
    Rev Med Suisse; 2011 Sep 07; 7(307):1683-8. PubMed ID: 21987876
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].
    Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S.
    Z Gastroenterol; 2012 Jan 07; 50(1):57-72. PubMed ID: 22222799
    [Abstract] [Full Text] [Related]

  • 38. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
    Asselah T, Marcellin P.
    Liver Int; 2012 Feb 07; 32 Suppl 1():88-102. PubMed ID: 22212578
    [Abstract] [Full Text] [Related]

  • 39. Telaprevir user's guide.
    Liapakis A, Jacobson I.
    Clin Liver Dis; 2011 Aug 07; 15(3):555-71. PubMed ID: 21867936
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.